- Home
- DIAX vs DAWN Comparison
DIAX vs DAWN Comparison
Compare DIAX & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DIAX
- DAWN
- Stock Information
- Founded
- DIAX 2005
- DAWN 2018
- Country
- DIAX United States
- DAWN United States
- Employees
- DIAX N/A
- DAWN N/A
- Industry
- DIAX Finance Companies
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- DIAX Finance
- DAWN Health Care
- Exchange
- DIAX Nasdaq
- DAWN Nasdaq
- Market Cap
- DIAX 528.0M
- DAWN 624.8M
- IPO Year
- DIAX N/A
- DAWN 2021
- Fundamental
- Price
- DIAX $14.94
- DAWN $9.44
- Analyst Decision
- DIAX
- DAWN Strong Buy
- Analyst Count
- DIAX 0
- DAWN 9
- Target Price
- DIAX N/A
- DAWN $26.56
- AVG Volume (30 Days)
- DIAX 96.6K
- DAWN 3.3M
- Earning Date
- DIAX 01-01-0001
- DAWN 11-04-2025
- Dividend Yield
- DIAX 7.93%
- DAWN N/A
- EPS Growth
- DIAX N/A
- DAWN N/A
- EPS
- DIAX N/A
- DAWN N/A
- Revenue
- DIAX N/A
- DAWN $133,672,000.00
- Revenue This Year
- DIAX N/A
- DAWN $12.88
- Revenue Next Year
- DIAX N/A
- DAWN $48.27
- P/E Ratio
- DIAX N/A
- DAWN N/A
- Revenue Growth
- DIAX N/A
- DAWN 31.11
- 52 Week Low
- DIAX $12.80
- DAWN $5.64
- 52 Week High
- DIAX $15.12
- DAWN $14.46
- Technical
- Relative Strength Index (RSI)
- DIAX 61.66
- DAWN 61.63
- Support Level
- DIAX $14.41
- DAWN $8.16
- Resistance Level
- DIAX $14.74
- DAWN $9.77
- Average True Range (ATR)
- DIAX 0.17
- DAWN 0.65
- MACD
- DIAX 0.02
- DAWN -0.01
- Stochastic Oscillator
- DIAX 91.30
- DAWN 47.85
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.